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ABSTRACT
Background. Canagliflozin is a sodium glucose co-
-transporter 2 (SGLT2) inhibitor that improves glyca-
emia in patients with type 2 diabetes mellitus (T2DM) 
by enhancing urinary glucose excretion (UGE). Indian 
data regarding comparative efficacy of canagliflozin 
300 mg over canagliflozin 100 mg in reduction of body 
weight are scanty.
Objectives. To evaluate and compare the efficacy of 
canagliflozin 100 mg versus canagliflozin 300 mg 
regarding loss of body weight retrospectively, in pa-
tients with T2DM inadequately controlled with other 
antihypergycaemic agents (AHA) in a real world setting 
in India.
Material and methods. T2DM patients inadequately 
controlled (HbA1c > 8.5%) with diet, exercise and AHA 
who were prescribed canagliflozin 100 mg (n = 62) or 
canagliflozin 300 mg (n = 36) once daily, between May 
2016 to May 2019 and were followed for at least 20 
weeks, are included in the analysis. Changes in blood 
pressure and glycaemic parameters and body weight 
are studied.
Results. Results show that addition of canagliflozin 100 
and 300 mg provided statistically significant impro-
vements in glycaemic control associated with weight 
loss. However no superiority of canagliflozin 300 mg 
to canagliflozin 100 mg is established.
Conclusion. The present study shows that addition 
of canagliflozin 300 mg has no advantage over ca-
nagliflozin 100 mg on body weight when added on 
existing therapy with other AHA. (Clin Diabetol 2020; 
9; 5: 300–305)
Key words: canagliflozin, SGLT2 inhibitors, T2DM
Background
The substantial increase in the incidence of type 
2 diabetes mellitus (T2DM) over the past decade is as-
sociated with a marked increase in the prevalence of 
obesity, which contributes greatly to insulin resistance, 
a key pathophysiologic parameter observed especially 
in individuals at risk. Given the role of obesity and 
sedentary lifestyles in contributing to the progression 
of T2DM, the first step in T2DM management is life-
style modification, exercise and weight loss [1]. With 
progressive deterioration in β-cell function (βCF) and 
mass, T2DM management progresses from non-phar-
macological treatment to monotherapy (metformin 
being the preferred first line drug), to the need for 
combination drugs. Drugs that can provide glycaemic 
control independent of βCF while having beneficial 
effects on weight are now preferred second line agent 
after metformin [2]. 
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Canagliflozin is a sodium glucose co-transporter 
2 (SGLT2) inhibitor developed for the treatment of 
patients with T2DM. SGLT2 found in the proximal 
renal tubule is a low affinity, high capacity transporter 
responsible for the majority (90.0%) of renal glucose 
reabsorption [3, 4]. Canagliflozin by inhibiting the 
SGLT2 co-transporter lowers the renal threshold for 
glucose (RTG range 4.4–5.0 mmol/l),thereby increas-
ing urinary glucose excretion (UGE) and resulting in 
decreased plasma glucose, a mild osmotic diuresis and 
increased caloric loss (4 kcal/g of glucose), with a low 
potential for hypoglycaemia [5–9]. The loss of glucose 
with attendant caloric loss contributes to weight loss; 
in addition, improvements in βCF have been seen [5, 8].
The recommended starting dose of canagliflozin 
is 100 mg once daily, taken before the first meal of 
the day. Dose can be increased to 300 mg once daily 
in patients tolerating canagliflozin 100 mg once daily 
who have an eGFR of 60 mL/min/1.73 m2 or greater 
and require additional glycaemic control [10]. Several 
randomized controlled studies have found that canagli-
flozin 300 mg is superior to sitagliptin and glimepiride 
as add-on therapy to metformin in achieving more 
effective glycaemic control [11–13].
The weight reducing effect of canagliflozin is an 
important therapeutic consideration for patients with 
T2DM who are overweight or obese. The incremental ef-
ficacy of canagliflozin 300 mg on reducing postprandial 
plasma glucose peaks, is consistent with the hypothesis 
that it transiently inhibits intestinal SGLT1-mediated 
glucose absorption-the major intestinal glucose trans-
porter, with perhaps a small contribution of delayed 
gastric emptying, possibly related to the increased 
glucagon-like peptide-1 (GLP-1) levels that assist in 
glycaemic and appetite control [14, 15]. Interestingly, 
canagliflozin 300 mg was found to significantly reduce 
body weight in obese and overweight patients without 
diabetes compared to placebo [16]. However there 
is paucity of real world data regarding superiority of 
canagliflozin 300 mg over canagliflozin 100 mg in 
reduction of body weight in Indian setting. This study 
compared the efficacy and weight loss benefit of two 
doses of canagliflozin (100 and 300 mg) as an add-on 
therapy in patients with T2DM inadequately controlled 
with other antihyperglycaemic agent (AHA).
Materials and methods
Study design
This retrospective, real-world observational study 
was conducted in a tertiary care setting in Kolkata to 
evaluate and compare the efficacy of two doses of 
canagliflozin 100 and 300 mg regarding weight loss 
potential in T2DM patients who were inadequately 
controlled (HbA1c > 8.5%) with diet, exercise and other 
AHAs. The patients underwent minimum 20 weeks 
treatment from May 2016 to May 2019.
Protocol characteristics
Eligible patients were adult (≥ 18 years) men and 
women with T2DM who had inadequate glycaemic 
control on diet, exercise and AHAs including oral an-
tidiabetic drugs (OAD), non-insulin injectable agents 
and insulin injections at maximally or near-maximally 
effective doses. Patients not adequately controlled were 
defined as either having one or more of the following 
parameters: fasting glucose (FPG) > 150 mg/dL, post 
prandial plasma glucose (PPPG) > 200 mg/dL, HbA1c 
> 8.5% despite receiving optimal dose of two or three 
antihypergycaemic agents [17]. Subjects were excluded 
if they had a history of type 1 diabetes, diabetic ketoaci-
dosis, alcohol or drug dependence, recent or multiple 
hospitalization for reasons other than hyper glycaemia 
within past six months, nursing women, history of 
urinary tract or other systemic infections, haematuria, 
decompensated heart failure, liver failure, debilitating 
illness that may adversely affect renal function or on 
drugs that may adversely affect renal function. Total 
98 patients who came to the study setting during the 
study period fitted the above mentioned criteria and 
were prescribed canagliflozin for a minimum period 
of 20 weeks. As weight change can also be affected 
by lifestyle therapy (diet and exercise), the subjects 
were advised at the beginning not to alter these and 
at subsequent visits the same was ensured. Compa-
rability between the two groups of patients receiving 
canagliflozin 100 and 300 mg was ensured. Decision on 
prescribing canagliflozin 100 mg or 300 mg was taken 
by examining physician based on patient’s body weight. 
Data collection
Baseline data of various parameters on the day of 
starting treatment with canagliflozin were collected 
from previous records. Data included all patients’ 
demographic records with respect to age, gender, 
anthropometric measurements like height, weight, 
body mass index (BMI) and clinical parameters like 
systolic blood pressure (SBP), diastolic blood pressure 
(DBP). Laboratory investigations data included HbA1c, 
FPG, PPPG, serum creatinine (Cr). Weight was recorded 
for each patient using an electronic weighing scale in 
the study setting following proper standardization 
procedure. BP was measured by mercury sphygmoma-
nometer. Cuff size of 16 × 30 cm was chosen while 
measuring BP for non-obese patients and larger cuff 
(16 × 36 cm) was used for obese patients. Plasma 
glucose was measured by hexokinase method and 
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HbA1c was measured by high performance liquid chro-
matographic (HPLC) method (Bio-RAD D-10, Bio-RAD, 
and Hercules, CA, USA) in the institute. Data were 
collected from only those patients who completed at 
least 20 weeks of treatment period with canagliflozin 
100 mg or 300 mg.
Recordings of body weight, SBP, DBP, HbA1c, FPG, 
PPPG, Cr in the study group at last follow-up were col-
lected from records. The primary parameter was change 
in weight from baseline at last follow up. Other sec-
ondary parameters studied included change in HbA1c, 
FPG, PPPG and SBP from baseline at final follow up. To 
evaluate safety profile of canaglifozin adverse events 
due to genital mycotic infections were noted.
Statistical analysis
The data were analysed using SPSS statistics ver-
sion 21. Comparability of both groups at baseline was 
assessed by independent t-test and nonparametric 
counterpart Mann-Whitney U test. Before treatment 
and after treatment efficacy data of canagliflozin 
within groups were analysed by paired sample t-test. 
To compare the efficacy of canagliflozin 300 mg with 
canagliflozin 100 mg in regards to body weight and 
BMI, ANCOVA was done. P value less than 0.05 was 
considered as statistically significant.
Results
In the present study, total 62 patients received 
canagliflozin 100 mg and were followed up a for a 
mean period of 25 weeks whereas 36 patients received 
canagliflozin 300 mg and were followed up a for a 
mean period of 24 weeks; patients were advised to take 
canagliflozin once daily before the first meal of the day.
Table 1 shows the baseline characteristics of the 
study subjects in the two groups receiving canagliflozin 
100 mg and canagliflozin 300 mg. Baseline patient 
demographic and disease characteristics were similar 
across the two groups except body weight which was 
significantly higher in the canagliflozin 300 mg treat-
ment group (Mann-Whitney U test, P = 0.0001).Overall 
the mean age of the patient was 52.12 years, 53.1% 
were male. Mean body weight was 78.81 kg and mean 
BMI was 29.68 kg/m2 with 45.9% patients classified as 
obese (according to WHO classification of obesity BMI ≥ 
30 kg/m2) [18]. Mean FPG and PPPG level were 164.82 
mg/dL and 214.18 mg/dL respectively. Baseline mean 
HbA1c was 8.33%.
Table 2 shows that both doses of canagliflozin 
significantly reduced bodyweight from baseline to final 
follow up (P < 0.001). Analysis of BMI also showed 
significant reduction in both canagliflozin groups 
(P value 0.001 and 0.002 respectively). 
As the baseline body weight differed significantly 
in the two groups, ANCOVA was done for adjustment 
for the baseline body weight and BMI. After adjustment 
of baseline body weight and BMI estimated mean treat-
ment differences between CANA 300 & CANA 100 with 
95% confidence interval were 1.41 (–0.902 to 1.878) and 
0.40 (–0.112 to 0.922) respectively which were not statis-
tically significant (P value 0.957 and 0.123 respectively). 
Table 3 shows glycaemic efficacy of the two doses 
of canagliflozin. HbA1c was significantly reduced from 
baseline with canagliflozin100 and 300 mg (P < 0.0001 
and 0.01 respectively). Subgroup analysis showed 
substantially greater reductions in HbA1c (P < 0.01) 
with both canagliflozin doses in patients with higher 
(HbA1c > 9%), relative to those with lower, baseline 
HbA1c. Proportion of patients who achieved HbA1c < 
7.0% at final follow up with canagliflozin 100 mg and 
300 mg were 31.1% and 27.8% respectively. Significant 
improvement from baseline in FPG was observed; P < 
0.001 for both canagliflozin doses. PPPG reduction 
was also noted to be significant (P ≤ 0.001 for both 
canagliflozin doses).
Reductions from baseline in SBP and DBP at week 
25 seen with canagliflozin 100 mg were statistically 
significant (P = 0.024 and 0.041 respectively). However 
reductions in SBP and DBP with canagliflozin 300 mg 
were found to be statistically insignificant.
Over the time, both canagliflozin doses were as-
sociated with higher rates of adverse events consistent 
with genital mycotic infections in the study groups. 
Frequency of genital mycotic infection associated with 
canagliflozin 100 mg and 300 mg was 21% and 11.1% 
respectively and the difference was statistically non-
significant (chi square, P > 0.05) (Table 4).
Discussion
In this study of subjects with T2DM who had inad-
equate glycaemic control with other AHA, treatment 
with canagliflozin 100 and 300 mg provided statistically 
significant improvements in glycaemic control over 25 
weeks and 24 weeks respectively; these improvements 
were associated with weight loss with both doses of 
canagliflozin.
Both treatment groups showed reductions in all 
glycaemic parameters — HbA1c, FPG, and PPPG. A large 
proportion of subjects reached HbA1c < 7.0% with 
canagliflozin. These results are consistent with reports 
from randomised controlled trials (RCT) conducted 
previously [13, 14, 19]. In the high glycaemic group 
(HbA1c > 9%), both canagliflozin doses substantially 
improved glycaemic parameters similar to results from 
previous study. Because UGE is proportional to the 
glucose concentration above RTG, subjects with higher 
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Table 1. Baseline demographic and disease characteristics of the overall study subjects (n = 98)
Study parameter CANA 100 mg 
(n = 62)





    Male







Age (years) 52.68 ± 8.79 51.17 ± 10.55 52.12 ± 9.45
Body weight [kg] 74.06 ± 10.62 86.99 ± 14.88 78.81 ± 13.78
BMI [kg/m2] 28.16 ± 3.92 32.31 ± 4.88 29.68 ± 4.72
SBP [mm Hg] 130.65 ± 13.69 131.00 ± 13.02 130.78 ± 13.38
DBP [mm Hg] 83.40 ± 8.38 83.56 ± 8.47 83.46 ± 8.37
HbA1c (%) 8.45 ± 1.65 8.16 ± 1.20 8.33 ± 1.50
FPG [mg/dL] 164.90 ± 46.14 164.68 ± 56.78 164.82 ± 50.02
PPPG [mg/dL] 214.50 ± 71.88 213.64 ± 63.27 214.18 ± 68.51
Serum Cr [mg/dL] 0.89 ± 0.20 0.87 ± 0.20 0.88 ± 0.20
Obesity, n (%) 18 (29.0) 27 (75.0) 45 (45.9)
Table 2. Changes from baseline in bodyweight and BMI at final follow up*
Canagliflozin  
doses
Baseline Final follow up Mean  
differences
t P value diff. 
within the 
groups
P value diff. 
between the 
groups 
Mean SD Mean SD
Body weight changes [kg]
CANA 100 mg (n = 62) 74.06 10.62 72.69 10.26 1.37 4.063 < 0.001 0.957
CANA 300 mg (n = 36) 86.99 14.88 85.08 14.58 1.91 3.839 < 0.001
BMI changes [kg/m2]
CANA 100 mg (n = 62) 28.16 3.92 27.62 3.79 0.54 3.646 0.001 0.123
CANA 300 mg (n = 36) 32.31 4.88 31.72 4.58 0.59 3.444 0.002
*Canagliflozin 100 mg — 25 weeks, canagliflozin 300 mg — 24 weeks. P < 0.05 considered as statistically significant, p value within the groups computed 
by paired sample t-test, P value between the groups computed by ANCOVA
Table 3. Summary of changes from baseline in glycaemic parameters and blood pressure at final follow up*
Canagliflozin doses Baseline Final follow up Mean  
differences
t p
Mean SD Mean SD
FPG [mg/dL]
CANA 100 mg (n = 62) 164.90 46.14 138.49 42.78 26.41 3.706 < 0.001
CANA 300 mg (n = 36) 164.68 56.78 128.36 25.63 36.32 4.113 < 0.001
PPPG [mg/dL]
CANA 100 mg (n = 62) 212.39 70.53 176.22 52.31 36.17 4.033 < 0.001
CANA 300 mg (n = 36) 213.64 63.27 173.39 42.24 40.25 3.581 0.001
HBA1c [%]
CANA 100 mg (n = 62) 8.435 1.6619 7.655 1.3143 0.78 4.834 < 0.0001
CANA 300 mg (n = 36) 8.115 1.2032 7.543 1.0058 0.572 2.581 0.014
SBP [mm Hg]
CANA 100 mg (n = 62) 130.65 13.69 127.92 11.19 2.73 2.261 0.024
CANA 300 mg (n = 36) 131.00 13.02 128.03 10.61 2.97 1.525 0.136
DBP [mm Hg]
CANA 100 mg (n = 62) 83.40 8.38 81.27 7.04 2.13 2.088 0.041
CANA 300 mg (n = 36) 83.56 8.47 81.42 7.87 2.14 1.423 0.164
*Canagliflozin 100 mg  — 25 weeks, canagliflozin 300 mg — 24 weeks. P < 0.05 considered as statistically significant, p computed by paired sample T-test
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baseline glucose level might be expected to show 
greater UGE and osmotic diuresis resulting in greater 
glycaemic efficacy of canagliflozin [14].
Addressing obesity is an important part of T2DM 
management. Because many of the traditional thera-
pies for T2DM result in weight gain, the added benefit 
of weight loss with canagliflozin is clinically useful [20]. 
In the present study canagliflozin 100 and 300 mg 
both showed significant body weight reduction from 
baseline similar to findings noted with other studies 
[13, 14, 19]. While body composition measurements 
were not performed in this study, analyses conducted 
in other phase 3 studies in patients with T2DM showed 
that approximately two-thirds of the reduction in body 
mass seen with canagliflozin was from fat mass and 
one-third was from lean body mass [13]. In clinical stud-
ies of weight loss, modest reductions in body weight 
have been associated with favourable improvements 
in cardiovascular risk factors, including lipids, BP, and 
inflammatory markers [21].
In the present study canagliflozin 100 mg was as-
sociated with a statistically significant reduction in SBP 
and DBP from baseline; however no such association 
was found in case of canagliflozin 300 mg though BP re-
duction was similar in both groups (mean differences in 
SBP –2.73 mm Hg in canagliflozin 100 mg, –2.97 mm Hg 
in canagliflozin 300 mg group and mean differences in 
DBP –2.13 mm Hg in canagliflozin 100 mg, –2.14 mm Hg 
in canagliflozin 300 mg group). This is in contrary to the 
previous studies which reported favourable improve-
ments in SBP with both doses of canagliflozin [14]. 
The above finding can be due to smaller sample size 
in canagliflozin 300 mg group. 
Relative to canagliflozin 100 mg an incremental 
efficacy on glycaemic endpoints, body weight and 
systolic BP of canagliflozin 300 mg was observed in 
a randomised controlled trial (RCT) conducted previ-
ously [14]. Clinical mechanism of action studies [15, 
22] have confirmed delayed gastrointestinal glucose 
absorption with canagliflozin 300 mg in healthy volun-
teers and subjects with T2DM. However in the present 
study, despite absolute weight reduction was higher in 
the canagliflozin 300 mg group (mean differences 1.91 
vs. 1.37 kg), this difference appeared to be insignificant. 
No significant difference was also found between the 
two doses of canagliflozin in respect to change of BMI 
although in this case difference was smaller (mean dif-
ferences 0.59 vs. 0.54 kg/m2). This lack of significance 
can probably be attributed to small study groups.
The observed frequencies of genital mycotic infec-
tion in this study in both canagliflozin groups were 
higher than in previous RCTs; these were generally 
mild or moderate in severity and treated by antifungal 
therapies [8, 19, 23, 24].
Finally the limitations of this study must be con-
sidered. One limitation of the study is small number of 
participants which may explain a lack of significance 
of some of the findings. Besides this is a real world 
study (RWS) and propensity score matching of the 
confounding factors between the two groups were 
not done due to limited sample size. Randomisation 
and placebo controlling was not possible in RWS. In 
addition, the treatment period under observation was 
short; a longer duration of observation with a larger 
sample size is needed to understand the comparative 
benefits and risks of these drugs and the durability of 
response. Finally, we did not assess the other potential 
adverse effects of canagliflozin like hypoglycaemia, pos-
tural dizziness and changes in eGFR. These issues might 
have implication in the result and outcome of the study. 
Conclusion
The present study showed that canagliflozin 100 
and 300 mg significantly improved glycaemic control, 
reduced body weight in subjects with T2DM inad-
equately controlled with diet, exercise and other AHA. 
Canagliflozin 100 mg additionally caused reduction 
in SBP and DBP. This the only Indian real world study 
is thus consistent with RCTs and real world studies of 
western world. However no superiority of canagliflozin 
300 mg to canagliflozin 100 mg in respect to body 
weight was established in this study.
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